Abstract A 62 year old woman taking L-tryptophan developed eosinophilic fasciitis shortly after starting an exercise class. She received prednisone without benefit but improved after azathioprine treatment was started and Ltryptophan was discontinued. As products containing L-tryptophan have recently been implicated in development of the eosinophiliamyalgia syndrome it is suggested that the use of L-tptophan might have contributed to the development of eosinophilic fasciitis in this patient. Similarities with toxic oil syndrome are noted. Additional studies are warranted to determine the prevalence of L-typtophan ingestion among patients diagnosed as having eosinophilic fasciitis.
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Eosinophilia-myalgia syndrome, an illness characterised by the presence of eosinophilia (> 109 cells/i) and generalised myalgias not explained by infection or neoplasm, has recently been linked to the ingestion of products containing L-tryptophan. 1 Other reported manifestations of this syndrome include ascending polyneuropathy and vasculitis. I wish to report the development of eosinophilic fasciitis in a patient taking L-tryptophan. Clinical suspicion of eosinophilic fasciitis led to the performance of a complete blood count, which showed white blood cell count 10 9x 109 cells/i with 35% eosinophils. Erythrocyte sedimentation rate was 18 mm/h. A biopsy specimen (from skin to muscle) of the left thigh showed striking oedema and fibrosis of septa in the subcutaneous fat and of the fascia. The dermis displayed a dense, predominantly lymphocytic, infiltrate. A similar infiltrate was present in the subcutaneous fat and fascia. These changes were consistent with eosinophilic fasciitis.
The patient was treated with prednisone (initially 40 mg daily and later 70 mg daily) without benefit. The induration progressed to affect the proximal right arm, which appeared 'puckered' (figure). Multiple papules, which evolved into ulcers, developed on the left leg; a biopsy showed dermal sclerosis with focal ulceration but no vasculitis. Treatment with azathioprine (100 mg daily) was started and prednisone was tapered and discontinued; the patient stopped using L-tryptophan. The The recently described association between the ingestion of products containing L-tryptophan and the development of eosinophilia with myalgias suggests that the use of L-tryptophan might have been a significant factor in the development of eosinophilic fasciitis in our patient. Whether the continued use of L-tryptophan made our patient's disease more refractory to treatment with the usual doses of corticosteroids is speculative. Also uncertain is the degree to which starting treatment with azathioprine v discontinuing L-tryptophan contributed to her clinical improvement.
The mechanism whereby L-tryptophan, an essential amino acid, or its metabolites may induce eosinophilia-myalgia syndrome and eosinophilic fasciitis is unknown. The illness that developed in our patient shares certain features with the toxic oil syndrome that occurred after ingestion of adulterated rapeseed oil in Spain.4 During the early phase of this syndrome patients presented with tender swelling and induration of the arms and legs associated with peripheral blood eosinophilia. Histological studies showed mononuclear cell infiltrates and eosinophils in the dermis, fascia, muscle, and vessel walls. Recently, Varga and coworkers also described the development of diffuse fasciitis with eosinophilia during L-tryptophan treatment; they showed increased expression of type I procollagen gene in dermal and fascial fibroblasts from two such patients.'
The recent popularity of products containing L-tryptophan may explain, in part, the increasing recognition of eosinophilic fasciitis. Additional studies are warranted to determine the prevalence of L-tryptophan ingestion among patients diagnosed as having eosinophilic fasciitis.
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